Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History LTRN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics LTRN

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Lantern Pharma Inc

LTRN
Current price
3.99 USD +0.23 USD (+6.12%)
Last closed 3.76 USD
ISIN US51654W1018
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 39 194 416 USD
Yield for 12 month -17.39 %
1Y
3Y
5Y
10Y
15Y
LTRN
21.11.2021 - 28.11.2021

Lantern Pharma Inc. focuses on the discovery and development of oncology drug. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases. The company was incorporated in 2013 and is headquartered in Dallas, Texas. Address: 1920 McKinney Avenue, Dallas, TX, United States, 75201

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

22.00 USD

P/E Ratio

Dividend Yield

Financials LTRN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures LTRN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

Last Year

Current Quarter

+100 654 USD

Last Quarter

Current Year

Last Year

-174 843 USD

Current Quarter

+50 327 USD

Last Quarter

EBITDA -21 240 672 USD
Operating Margin TTM
Price to Earnings
Return On Assets TTM -43.68 %
PEG Ratio
Return On Equity TTM -75.66 %
Wall Street Target Price 22.00 USD
Revenue TTM
Book Value 1.56 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -1.84 USD
Diluted Eps TTM -1.84 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation LTRN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA 0.21
Price Book MRQ 2.18

Technical Indicators LTRN

For 52 Weeks

2.55 USD 6.12 USD
50 Day MA 3.40 USD
Shares Short Prior Month 276 153
200 Day MA 3.64 USD
Short Ratio 3.77
Shares Short 262 123
Short Percent 2.91 %